CY1108730T1 - Θεραπεια ασθενειας hundington με epa - Google Patents

Θεραπεια ασθενειας hundington με epa

Info

Publication number
CY1108730T1
CY1108730T1 CY20091100029T CY091100029T CY1108730T1 CY 1108730 T1 CY1108730 T1 CY 1108730T1 CY 20091100029 T CY20091100029 T CY 20091100029T CY 091100029 T CY091100029 T CY 091100029T CY 1108730 T1 CY1108730 T1 CY 1108730T1
Authority
CY
Cyprus
Prior art keywords
epa
hundington
disease treatment
huntington
disease
Prior art date
Application number
CY20091100029T
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Amarin Neuroscience Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Neuroscience Limited filed Critical Amarin Neuroscience Limited
Publication of CY1108730T1 publication Critical patent/CY1108730T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Ανάλυση γονιδίου Hundington παρέχει μέθοδο πιστοποίησης ασθενών που πιθανώς ανταποκρίνονται σε θεραπεία ασθένειας Hundington με εικοσαπενταενοϊκό οξύ, EPA.
CY20091100029T 2002-12-02 2009-01-14 Θεραπεια ασθενειας hundington με epa CY1108730T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228079.0A GB0228079D0 (en) 2002-12-02 2002-12-02 Huntington's Disease
EP03778516A EP1567667B1 (en) 2002-12-02 2003-11-26 Treatment of huntington's disease with epa

Publications (1)

Publication Number Publication Date
CY1108730T1 true CY1108730T1 (el) 2014-04-09

Family

ID=9948921

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100029T CY1108730T1 (el) 2002-12-02 2009-01-14 Θεραπεια ασθενειας hundington με epa

Country Status (29)

Country Link
US (2) US20070148643A1 (el)
EP (1) EP1567667B1 (el)
JP (1) JP2006507833A (el)
KR (1) KR20050086895A (el)
CN (1) CN1717497A (el)
AT (1) ATE411399T1 (el)
AU (1) AU2003285519A1 (el)
BR (1) BR0316969A (el)
CA (1) CA2506727A1 (el)
CY (1) CY1108730T1 (el)
DE (1) DE60324180D1 (el)
DK (1) DK1567667T3 (el)
ES (1) ES2315543T3 (el)
GB (1) GB0228079D0 (el)
HK (1) HK1081598A1 (el)
HR (1) HRP20050493A2 (el)
IS (1) IS7842A (el)
MX (1) MXPA05005908A (el)
MY (1) MY138759A (el)
NO (1) NO20052955L (el)
NZ (1) NZ539989A (el)
PL (1) PL376101A1 (el)
PT (1) PT1567667E (el)
RU (1) RU2332209C2 (el)
SI (1) SI1567667T1 (el)
TW (1) TWI306120B (el)
UA (1) UA86582C2 (el)
WO (1) WO2004050913A1 (el)
ZA (1) ZA200504003B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524674A (ja) * 2004-01-19 2007-08-30 マーテック・バイオサイエンシーズ・コーポレーション リーリン欠損症または機能障害およびそれに関連する方法
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
DK2049664T3 (da) 2006-08-11 2012-01-02 Prosensa Technologies Bv Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
JP5706157B2 (ja) 2007-07-12 2015-04-22 プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． 化合物を種々の選択臓器又は組織に標的化するための分子
JP2010533170A (ja) 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー．ブイ． 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子
EP2203173B1 (en) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009099326A1 (en) 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
PT3037089T (pt) 2009-02-10 2020-03-04 Amarin Pharmaceuticals Ie Ltd Ester etílico de ácido eicosapentaenoico para tratamento de hipertrigliceridemia
US20120046342A1 (en) 2009-04-24 2012-02-23 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
RU2624506C2 (ru) 2009-04-29 2017-07-04 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения
EP2424356B1 (en) 2009-04-29 2017-08-23 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
EP3698781A1 (en) 2009-06-15 2020-08-26 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
JP6141018B2 (ja) 2009-12-24 2017-06-07 バイオマリン テクノロジーズ ベー．フェー． 炎症性障害を治療するための分子
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
CN104203289B (zh) 2012-01-27 2020-11-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
PT3363433T (pt) 2012-06-29 2021-02-15 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de um episódio cardiovascular num indivíduo em terapia com estatina utilizando éster etílico do ácido eicosapentaenoico
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
SG11202102872QA (en) 2018-09-24 2021-04-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
CA2216057A1 (en) * 1997-09-19 1999-03-19 Ridha Joober Polymorphic cag repeat-containing gene, diagnosis of psychiatric diseases and therapeutic uses thereof
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物

Also Published As

Publication number Publication date
ES2315543T3 (es) 2009-04-01
WO2004050913A1 (en) 2004-06-17
ATE411399T1 (de) 2008-10-15
GB0228079D0 (en) 2003-01-08
TWI306120B (en) 2009-02-11
AU2003285519A1 (en) 2004-06-23
ZA200504003B (en) 2007-01-31
NZ539989A (en) 2006-11-30
US20090270504A1 (en) 2009-10-29
DK1567667T3 (da) 2009-01-12
UA86582C2 (ru) 2009-05-12
HRP20050493A2 (en) 2005-10-31
US20070148643A1 (en) 2007-06-28
SI1567667T1 (sl) 2009-04-30
MY138759A (en) 2009-07-31
TW200418993A (en) 2004-10-01
CA2506727A1 (en) 2004-06-17
BR0316969A (pt) 2005-10-25
RU2332209C2 (ru) 2008-08-27
RU2005115536A (ru) 2006-01-27
EP1567667A1 (en) 2005-08-31
EP1567667B1 (en) 2008-10-15
JP2006507833A (ja) 2006-03-09
PL376101A1 (en) 2005-12-12
KR20050086895A (ko) 2005-08-30
NO20052955L (no) 2005-06-16
IS7842A (is) 2005-05-12
CN1717497A (zh) 2006-01-04
MXPA05005908A (es) 2005-12-12
DE60324180D1 (de) 2008-11-27
HK1081598A1 (en) 2006-05-19
PT1567667E (pt) 2008-11-04

Similar Documents

Publication Publication Date Title
CY1108730T1 (el) Θεραπεια ασθενειας hundington με epa
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
WO2005099716A3 (en) Method for analyzing the biological age of a subject
EA200401365A1 (ru) Способы лечения илеуса
BR0200350A (pt) Bactéria produtora de l-aminoácido pertencente ao gênero escherichia, e, método produzir l-aminoácido
NO20044436L (no) Substituerte fenyleddiksyrer
NO20050063L (no) 2-heteroaryl karboksamider
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
BRPI0214821B8 (pt) método para determinar a responsividade de indivíduo com distúrbio psicótico ao tratamento com loperidona
ATE531813T1 (de) System zur überwachung einer bakteriellen tumorbehandlung
GB0208041D0 (en) Method of culturing animal cells
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
PT1267915E (pt) Metodos para tratar doencas com proteina c activada
DK1295611T3 (da) Oligonukleotid-transformerende forbindelser
SE0300959D0 (sv) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
BR0001112A (pt) Solução aquosa estável e processo para sua produção
DE60305279D1 (de) Verwendung von Methyltestosteron zur Behandlung von menschlichen Papillomavirus Infektionen
ATE462699T1 (de) Substituierte 4,5,6,7-tetrahydro-benzothiazol-2- ylamin-verbindungen
WO2007092609A3 (en) Method for treating peripheral arterial disease with zinc finger proteins
WO2003107545A3 (en) TECHNIQUES FOR IDENTIFYING COMPOUNDS FOR TREATING PATHOLOGICAL CONDITIONS
DE602006020601D1 (de) Verfahren zur verwendung von il-21
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten